Discovery & Development of S-4321, a Novel PD-1 FcgRIIb Dual Cell Bidirectional (DcB) Agonist Antibody

By | 9 April 2026

• Current approaches to checkpoint agonism in autoimmunity

• Concept of Dual Cell Bidirectional antibodies

• Discovery and development of S-4321, a novel PD-1 FcgRIIb dual cell bidirectional (DcB) agonist antibody